SCHEMBL3555724

SCHEMBL3555724

CCC1(C)NCCN(CC(=O)NCCN(C)C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 2/20 0.36
DDR1 Q08345 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 1/20 0.35
DNM1 Q05193 1/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 2/20 0.32
TP53 P04637 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
LGALS1 P09382 1/20 0.32
POLB P06746 2/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542513 0.88 OPRM1 (0.40) L3MBTL1LMNADDR1OPRM1OPRL1
SCHEMBL3545537 0.82 L3MBTL1 (0.41) L3MBTL1ALDH1A1MEN1KMT2AGAA
SCHEMBL3547086 0.80 GAA (0.44) L3MBTL1LMNAKMT2AGAAKDM4E
SCHEMBL3546208 0.78 KDM4E (0.33) LMNAALDH1A1KDM4EMAPT
SCHEMBL3547224 0.76 HSD17B10 (0.38) L3MBTL1LMNAALDH1A1KDM4EUSP2
SCHEMBL3552851 0.70 POLB (0.35) L3MBTL1DDR1KMT2AGAAMAPT
SCHEMBL11553497 0.69 HTT (0.50) LMNAOPRM1OPRL1KMT2A
Hydrochloric Acid SCHEMBL11555232 0.68 HTT (0.49) LMNAOPRM1OPRL1KMT2AKDM4E
SCHEMBL3548903 0.68
SCHEMBL3541852 0.67 ACE (0.39) MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 L3MBTL1 3206/4885LMNA 2936/4885DDR1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.